VIRI

Dogwood Therapeutics Inc. (VIRI) | Rumor.io

Dogwood Therapeutics

VIRI

Attention (50-day avg)0%

Attention rank (50-day avg)—

Bullish sentiment (50-day avg)100%

Price to earnings ratio-0.19

Market capitalization1M

Earnings per share-7

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-5.3M

Social

What share of all stock conversation is about VIRI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 23

Virios Therapeutics, Inc. (VIRI) was held by an investor since its IPO in 2021, with 2048 shares sold in December 2022.
The stock was previously known as Virios Therapeutics and has seen significant price action, including a 700% rise in the past.
VIRI's performance is being compared to that of VTGN, with the latter considered a good buying opportunity.

Generated by AI

Sentiment

Of the messages about VIRI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.73% +42.68
Bearish	—	—	—	20.27% -42.68

Oct 8

Virios Therapeutics, Inc. ($VIRI) has a strong uptrend, breaking a downtrend and showing high relative strength.
The stock has made significant gains, increasing by over 46% since the last post, and is aiming for a price of $0.25.
$VIRI has received a boost from a $19.5M financing announcement and merger, focusing on key pipeline developments, resulting in a stock price increase of over 18%.

Generated by AI

Topics

Of the messages about VIRI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	88.11%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	11.89%

Nov 2

Virios Therapeutics, Inc. ($VIRI) announced plans to progress its IMC-1 program to a Phase 3 trial following FDA guidance.
The company has submitted briefing materials to the FDA for IMC-2, a treatment for Alzheimer's disease, and plans to progress it to a Phase 3 study.
$VIRI stock price surged 32.61% due to news of a potential partnership and FDA guidance for its IMC-1 program to treat fibromyalgia.

Generated by AI

Community

Of the messages about VIRI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	52.92%
Newcomers	—	—	—	47.08%

Regulars· Oct 8

The $VIRI stock price surged over 46% from the previous post, with some traders wondering if it will gain even more.
$VIRI stock price surged over 26% after a merger announcement and $19.5M financing for new drug pipeline focused on pain and COVID.
The complete float of Virios Therapeutics $VIRI has been traded, with 26.1M shares traded, making it one of the most actively traded stocks.

Newcomers· Oct 8

The merger news for Virios Therapeutics ($VIRI) has sparked interest, with some expecting the stock to react more strongly.
The company has completed its final share exchange agreement with Sealbond, a subsidiary of Wex Pharmaceuticals, on October 7, 2024.
New investors are being introduced to the merged entity, Dogwood, which was previously a part of CKLIFE SCIENCES, potentially leading to increased activity in $VIRI stock.

Generated by AI

Also Discussed

Investors talking about VIRI also mention

#	Name	Attention
1	SONN - Sonnet BioTherapeutics Holdings, Inc.	——
2	NVOS - Novo Integrated Sciences, Inc.	——
3	Cosmos Health Inc.COSM	0.02%+0.01
4	YS - YS Biopharma Co., Ltd.	——
5	ZVSA - ZyVersa Therapeutics, Inc.	——
6	TRKA - Troika Media Group, Inc.	——
7	Processa Pharmaceuticals Inc.PCSA	0%0
8	Mangoceuticals, Inc.MGRX	0%0
9	Splash Beverage Group Inc.SBEV	0%new
10	GT Biopharma Inc.GTBP	0%0

Dogwood Therapeutics Inc.

Healthcare
Biotechnology

Dogwood Therapeutics Inc. is a biotechnology company dedicated to developing innovative treatments for infectious diseases. The primary focus of Dogwood Therapeutics is on leveraging advanced medical research and technology to identify and develop novel therapeutics that address unmet medical needs in the area of viral infections. By concentrating on innovative drug discovery and clinical development, the company aims to produce solutions that transform the landscape of healthcare for patients worldwide. Dogwood Therapeutics operates at the intersection of biotechnology and healthcare, impacting sectors such as pharmacology, virology, and medicinal chemistry. This company plays a crucial role in the financial market by contributing to the medical advancements required for combating complex viral diseases, thereby being an integral part of the broader biosciences investment landscape. As biotechnology continues to be a significant driver of innovation, Dogwood Therapeutics represents an essential player in the pursuit of improving human health through pioneering medical interventions.

Website

Location

44 Milton Avenue

Alpharetta, GA, 30009

United States

Social

What share of all stock conversation is about VIRI?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% 0	0% 0	0% 0

Jan 23

Virios Therapeutics, Inc. (VIRI) was held by an investor since its IPO in 2021, with 2048 shares sold in December 2022.
The stock was previously known as Virios Therapeutics and has seen significant price action, including a 700% rise in the past.
VIRI's performance is being compared to that of VTGN, with the latter considered a good buying opportunity.

Generated by AI

Sentiment

Of the messages about VIRI that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	—	—	79.73% +42.68
Bearish	—	—	—	20.27% -42.68

Oct 8

Virios Therapeutics, Inc. ($VIRI) has a strong uptrend, breaking a downtrend and showing high relative strength.
The stock has made significant gains, increasing by over 46% since the last post, and is aiming for a price of $0.25.
$VIRI has received a boost from a $19.5M financing announcement and merger, focusing on key pipeline developments, resulting in a stock price increase of over 18%.

Generated by AI

Topics

Of the messages about VIRI that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Analysts	—	—	—	0%
Announcements	—	—	—	88.11%
Controversies	—	—	—	0%
Earnings	—	—	—	0%
Macro	—	—	—	0%
Technical Analysis	—	—	—	11.89%

Nov 2

Virios Therapeutics, Inc. ($VIRI) announced plans to progress its IMC-1 program to a Phase 3 trial following FDA guidance.
The company has submitted briefing materials to the FDA for IMC-2, a treatment for Alzheimer's disease, and plans to progress it to a Phase 3 study.
$VIRI stock price surged 32.61% due to news of a potential partnership and FDA guidance for its IMC-1 program to treat fibromyalgia.

Generated by AI

Community

Of the messages about VIRI, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	—	—	—	52.92%
Newcomers	—	—	—	47.08%

Regulars· Oct 8

The $VIRI stock price surged over 46% from the previous post, with some traders wondering if it will gain even more.
$VIRI stock price surged over 26% after a merger announcement and $19.5M financing for new drug pipeline focused on pain and COVID.
The complete float of Virios Therapeutics $VIRI has been traded, with 26.1M shares traded, making it one of the most actively traded stocks.

Newcomers· Oct 8

The merger news for Virios Therapeutics ($VIRI) has sparked interest, with some expecting the stock to react more strongly.
The company has completed its final share exchange agreement with Sealbond, a subsidiary of Wex Pharmaceuticals, on October 7, 2024.
New investors are being introduced to the merged entity, Dogwood, which was previously a part of CKLIFE SCIENCES, potentially leading to increased activity in $VIRI stock.

Generated by AI

Dogwood Therapeutics

Social

Jan 23

Sentiment

Oct 8

Topics

Nov 2

Community

Regulars· Oct 8

Newcomers· Oct 8

Also Discussed

Dogwood Therapeutics Inc.

Company Information

Location

Also Discussed

Social

Jan 23

Sentiment

Oct 8

Topics

Nov 2

Community

Regulars· Oct 8

Newcomers· Oct 8